Boston Scientific Change in Assets/Liabilities 2010-2024 | BSX
Boston Scientific annual/quarterly change in assets/liabilities history and growth rate from 2010 to 2024. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
- Boston Scientific change in assets/liabilities for the quarter ending September 30, 2024 was $-0.109B, a 153.49% increase year-over-year.
- Boston Scientific change in assets/liabilities for the twelve months ending September 30, 2024 was $-0.284B, a 18.86% decline year-over-year.
- Boston Scientific annual change in assets/liabilities for 2023 was $0.01B, a 104.78% decline from 2022.
- Boston Scientific annual change in assets/liabilities for 2022 was $-0.209B, a 55.97% increase from 2021.
- Boston Scientific annual change in assets/liabilities for 2021 was $-0.134B, a 49.43% decline from 2020.
| Boston Scientific Annual Change in Assets/Liabilities (Millions of US $) |
|
|---|---|
| 2023 | $10 |
| 2022 | $-209 |
| 2021 | $-134 |
| 2020 | $-265 |
| 2019 | $45 |
| 2018 | $-1,336 |
| 2017 | $8 |
| 2016 | $-171 |
| 2015 | $360 |
| 2014 | $370 |
| 2013 | $300 |
| 2012 | $312 |
| 2011 | $46 |
| 2010 | $-272 |
| 2009 | $554 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $131.731B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $196.757B | 25.10 |
| Stryker (SYK) | United States | $136.750B | 30.82 |
| EssilorLuxottica (ESLOY) | France | $109.710B | 0.00 |
| Medtronic (MDT) | Ireland | $102.865B | 15.28 |
| Haleon (HLN) | United Kingdom | $42.732B | 27.76 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.382B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $35.810B | 18.57 |
| ResMed (RMD) | United States | $33.540B | 27.56 |
| Terumo (TRUMY) | Japan | $28.681B | 40.51 |
| Koninklijke Philips (PHG) | Netherlands | $23.480B | 17.97 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.795B | 13.24 |
| Insulet (PODD) | United States | $18.017B | 71.75 |
| Baxter (BAX) | United States | $14.940B | 9.72 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.667B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.606B | 38.65 |
| Bio-Rad Laboratories (BIO) | United States | $9.131B | 31.03 |
| Demant (WILYY) | Denmark | $8.251B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.174B | 14.35 |
| Haemonetics (HAE) | United States | $3.938B | 19.22 |
| ICU Medical (ICUI) | United States | $3.868B | 36.83 |
| Prestige Consumer Healthcare (PBH) | United States | $3.840B | 19.10 |
| Perrigo (PRGO) | Ireland | $3.547B | 10.44 |
| Envista Holdings (NVST) | United States | $3.289B | 24.50 |
| QuidelOrtho (QDEL) | United States | $3.029B | 19.50 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.863B | 18.36 |
| Neogen (NEOG) | United States | $2.587B | 29.85 |
| LeMaitre Vascular (LMAT) | United States | $2.057B | 49.98 |
| Green Thumb Industries (GTBIF) | United States | $1.724B | 30.17 |
| AtriCure (ATRC) | United States | $1.482B | 0.00 |
| InMode (INMD) | Israel | $1.424B | 8.57 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.386B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.305B | 9.33 |
| BioLife Solutions (BLFS) | United States | $1.214B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.066B | 0.00 |
| Owens & Minor (OMI) | United States | $0.991B | 7.74 |
| CeriBell (CBLL) | United States | $0.926B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.840B | 14.81 |
| Evolus (EOLS) | United States | $0.704B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.680B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.594B | 26.20 |
| Omeros (OMER) | United States | $0.570B | 0.00 |
| Surmodics (SRDX) | United States | $0.567B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.502B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.463B | 0.00 |
| Quanterix (QTRX) | United States | $0.415B | 0.00 |
| Valneva SE (VALN) | France | $0.384B | 0.00 |
| ZimVie (ZIMV) | United States | $0.382B | 32.16 |
| Biote (BTMD) | United States | $0.328B | 7.18 |
| Viemed Healthcare (VMD) | United States | $0.317B | 30.11 |
| Canopy Growth (CGC) | Canada | $0.314B | 0.00 |
| Cerus (CERS) | United States | $0.292B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.289B | 0.00 |
| High Tide (HITI) | Canada | $0.269B | 110.67 |
| OraSure Technologies (OSUR) | United States | $0.264B | 17.70 |
| Zynex (ZYXI) | United States | $0.249B | 52.07 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.209B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.208B | 14.37 |
| MacroGenics (MGNX) | United States | $0.207B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.205B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.180B | 95.80 |
| TriSalus Life Sciences (TLSI) | United States | $0.152B | 0.00 |
| Jin Medical (ZJYL) | China | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.148B | 18.59 |
| Quipt Home Medical (QIPT) | United States | $0.125B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.097B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.79 |
| Veru (VERU) | United States | $0.095B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.072B | 37.00 |
| Jushi Holdings (JUSHF) | United States | $0.065B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.060B | 0.00 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Exagen (XGN) | United States | $0.055B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.049B | 0.00 |
| ImmuCell (ICCC) | United States | $0.047B | 0.00 |
| Safety Shot (SHOT) | United States | $0.045B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.027B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.84 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |